Stay updated on Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page
- CheckyesterdayChange DetectedAdded a Publications entry for the 2026 Oncologist article with PubMed auto-fill notes and removed the Revision: v3.4.3 entry.SummaryDifference0.3%

- Check8 days agoChange DetectedThe page now shows Revision: v3.4.3, replacing Revision: v3.4.2.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check37 days agoChange DetectedSite update from v3.4.1 to v3.4.2 involves minor UI/bug fixes and no substantive changes to the study record or its critical information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check44 days agoChange DetectedRevision: v3.4.1 is now displayed, replacing the previous v3.4.0. This is a minor site metadata update and does not alter the study details.SummaryDifference0.1%

- Check51 days agoChange DetectedShow glossary added and ORR/DCR definitions updated to RECIST 1.1 criteria with duration notes (e.g., 'Throughout study duration, up to approx 80 months'). Additionally, metadata updates were added, including 'Last Update Submitted that Met QC Criteria', 'Revision: v3.4.0', and 'No FEAR Act Data'.SummaryDifference0.8%

- Check66 days agoChange DetectedThe page revision label changed from v3.3.3 to v3.3.4, a minor metadata update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.